Last checked at 27 Oct 2017 10:32
27 October 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PDMR AND PERSONS CLOSELY ASSOCIATED WITH THEM
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announces that on 25 October 2017, share options over 420,000 £0.01 ordinary shares of the Company were awarded to staff and directors (who are PDMRs) under the Company's 2016 Share Option Plan (an amalgamation of the Company's 2005 and 2007 Share Option Plans) as follows.
Name | Position | Number of Share Options Awarded | Exercise price per Share | Percentage of issued ordinary share capital |
Meinhard Schmidt | Non-executive Chairman | 300,000 | £1.215 | 0.552% |
Andrew Millet | Chief Financial Officer | 30,000 | £1.215 | 0.055% |
Other employees (not directors or PDMR's) |
| 90,000 | £1.215 | 0.165% |
The options are subject to the rules of the 2016 Share Option Plan and vest in five equal annual parts, the first fifth vesting on 27 October 2018 and each year thereafter for a further four years, subject to continued employment. Unless otherwise indicated in the table above, the options are exercisable at 121.5 pence, being the mid-market price of the Company's ordinary shares at the close of day on 25 October 2017
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Giles Balleny
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Meinhard Schmidt | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Non-Executive Chairman, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Oncimmune Holdings plc | ||||
b) | LEI | 213800HCYIWT6YPI1I02 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | options over 1p ordinary shares - 2016 Share Option Plan
ISIN GB00BYQ94H38 | ||||
b) | Nature of the transaction
| Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 25 October 2016 | ||||
f) | Place of the transaction
| N/A | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) | Name
| Andrew Millet | ||||||
2 | Reason for the notification | |||||||
a) | Position/status
| Chief Financial Officer, Director | ||||||
b) | Initial notification/Amendment
| Initial Notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Oncimmune Holdings Plc | ||||||
b) | LEI | 213800HCYIWT6YPI1I02 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument
Identification code | options over 1p ordinary shares - 2016 Share Option Plan
ISIN GB00BYQ94H38 | ||||||
b) | Nature of the transaction
| Grant of options over ordinary shares | ||||||
c) | Price(s) and volume(s)
|
| ||||||
d) | Aggregated information
|
| ||||||
e) | Date of the transaction
| 25 October 2017 | ||||||
f) | Place of the transaction
| N/A | ||||||